and gene-based therapies.

Brammer Bio is focused on providing clinical and commercial supply of autologous and allogeneic cell therapies, and viral vector products for in vivo and ex vivo therapeutic applications.

Along with process and analytical development and regulatory support we enable large pharma and biotech clients to accelerate the delivery of novel medicines and improve patient health.

Brammer Bio occupies 45,000 ft2 of process development and phase I/II clinical manufacturing space in Alachua, FL, and is developing a 50,000 ft2 facility in Lexington, MA, with plans to build-out large-scale, phase III/commercial ready viral vector manufacturing suites, segregated cell and gene therapy suites, and QC and analytical laboratories for clinical and commercial launch services.